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Data for reference
The TRACK-HD and Enroll-HD clinical data
that support the ﬁndings of this study are
available for approved studies from CHDI
(https://chdifoundation.org) and
https://www.enroll-hd.org/for-researchers/
access-data/ respectively, but restrictions
apply to the availability of these data,
which were used under license for the
current study, and so are not publicly
available. The linked novel data generated
here are available from the authors upon
request (darren.monckton@glasgow.ac.uk),
subject to approval from TRACK-HD and/or
Enroll-HD as appropriate.
a b s t r a c t
Background: Huntington disease (HD) is caused by an unstable CAG/CAA repeat expansion encoding a
toxic polyglutamine tract. Here, we tested the hypotheses that HD outcomes are impacted by somatic
expansion of, and polymorphisms within, the HTT CAG/CAA glutamine-encoding repeat, and DNA repair
genes.
Methods: The sequence of the glutamine-encoding repeat and the proportion of somatic CAG expansions
in blood DNA from participants inheriting 40 to 50 CAG repeats within the TRACK-HD and Enroll-HD
cohorts were determined using high-throughput ultra-deep-sequencing. Candidate gene polymorphisms
were genotyped using kompetitive allele-speciﬁc PCR (KASP). Genotypic associations were assessed using
time-to-event and regression analyses.
Findings: Using data from 203 TRACK-HD and 531 Enroll-HD participants, we show that individuals
with higher blood DNA somatic CAG repeat expansion scores have worse HD outcomes: a one-unit in-
crease in somatic expansion score was associated with a Cox hazard ratio for motor onset of 3·05 (95%
CI=1·94 to 4·80, p=1·3 × 10−6). We also show that individual-speciﬁc somatic expansion scores are
associated with variants in FAN1 (pFDR=4·8×10-6), MLH3 (pFDR=8·0×10−4), MLH1 (pFDR=0·004) and
MSH3 (pFDR=0·009). We also show that HD outcomes are best predicted by the number of pure CAGs
rather than total encoded-glutamines.
Interpretation: These data establish pure CAG length, rather than encoded-glutamine, as the key inherited
determinant of downstream pathophysiology. These ﬁndings have implications for HD diagnostics, and
∗ Corresponding author.
E-mail address: darren.monckton@glasgow.ac.uk (D.G. Monckton).
1 Investigators listed in the appendix.
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support somatic expansion as
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hesearch in context
vidence before this study
Huntington disease (HD), a devastating neurodegenerative con-
ition with a prevalence of ∼1/10000, is caused by the expan-
ion of a CAG/CAA repeat in exon one of the HTT gene. The ex-
anded CAG/CAA tract encodes for glutamine in the HTT protein,
nd pathology is assumed to primarily result as a toxic gain of
unction of the mutant polyglutamine containing protein. More re-
eats cause an earlier age at onset, however, measured inherited
AG length only accounts for ∼60% of the variation in age at onset.
e sought to identify genetic variants that modify residual varia-
ion in HD outcomes not accounted for by measured CAG length
nd determine their mode of action. All searches were conducted
n PubMed for articles published from January 1st 1984 until April
0th 2019. Language was not restricted, however, PubMed is bi-
sed toward English language journals. Nonetheless, although rare,
D is a high-proﬁle disorder and recent important genetic stud-
es are likely to have been published in English. Initially, we used
he search terms “Huntington∗ disease” AND “modiﬁer gene” AND
pecies “human” AND publication type NOT “review”. This identi-
ed 53 reports, most of which were candidate gene studies that
ere superseded by two genome-wide association studies (GWAS).
hese revealed genome-wide signiﬁcant hits at the RRM2B/UBR5,
AN1 and MSH3 loci, and a highly suggestive hit at the MLH1 locus
hat was conﬁrmed in a follow-up study. As some of these genes
re known modiﬁers of somatic expansion in animal models, these
ata suggested that their effects on disease severity might be me-
iated through somatic expansion of the CAG repeat. We thus also
sed the search terms “Huntington∗ disease” AND “somatic expan-
ion” AND species “human” and publication type NOT “review”.
his identiﬁed 55 reports, most of which were studies in other dis-
ases or model organisms, or small-scale largely non-quantitative
nalyses of somatic expansion in HD patients. Several critical stud-
es reported large expansions in HD patient brains, with one key
tudy revealing an association between the degree of skewness
f somatic expansions in the cortex of end-stage patients and ex-
reme variation in age at onset. There were no large-scale system-
tic quantitative analyses of the frequency of somatic expansions in
he peripheral tissues of HD patients. It is well known in other dis-
rders that the presence of variant repeat interruptions within the
epeat array can modulate the germline instability of repeat expan-
ions. Using the search terms “Huntington∗ disease” AND “repeat
nterruption” AND species “human” and publication type NOT “re-
iew” revealed no studies. However, we were aware of two 1995
eports by Pêcheux et al., and Goldberg et al., describing atypical
tructures of the HTT exon one CAG/CAA repeat. These studies were
ubsequently cited in 146 publications, eight of which described
are sequence variants in the HTT exon one repeat. Articles citing
hese studies were investigated, revealing one additional study de-
cribing an atypical HTT exon one repeat allele. All of these studies
ere small, mostly anecdotal case reports, and none provided any
uantitative data in support of an effect on HD clinical outcomes.
ome available evidence suggests that loss of the CAA repeat inter-
uption might be associated with an increased risk of intergenera-
ional expansion of intermediate alleles (27 to 35 CAG repeats), buta mechanistic link for genetic modiﬁers of clinical outcomes, a driver of
tic target in HD and related repeat expansion disorders.
© 2019 The Authors. Published by Elsevier B.V.
cle under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
one of the studies was powered to provide a deﬁnitive answer to
his question. None of the studies reported any effect of the pres-
nce or absence of repeat sequence interruptions on the somatic
nstability of HTT alleles.
dded value of this study
We present a high-throughput ultra-deep sequencing method
o reveal the frequency of synonymous CAA repeat interruptions in
he HTT CAG/CAA repeat and determined that pure CAG length, not
otal encoded-glutamine number, better explains clinical outcomes
n HD, and that mis-sizing of the expanded pure CAG tract using
tandard fragment length may yield misleading estimates of pre-
icted HD outcomes. We precisely quantiﬁed the ratio of somatic
AG expansions in blood DNA, and revealed that somatic expan-
ions are also better predicted by pure CAG length, and that in-
ividuals with more somatic expansions tend to have worse clini-
al outcomes, including an earlier age at onset, higher baseline to-
al motor score and, in TRACK-HD, higher progression scores. We
lso established that variants in DNA repair genes FAN1, MSH3 and
LH1, previously identiﬁed by GWASs of HD onset and progres-
ion, and MLH3, previously implicated by pathway analysis and
nimal models, are associated with somatic expansion scores in
lood DNA.
mplications of all the available evidence
These data suggest that consideration should be given in the
uture to potentially replacing fragment length analysis using a
equence-based approach to genotyping HD in order to improve
iagnostic accuracy, prognostic precision and the power of clinical
rials. This might be particularly clinically relevant for people with
epeat lengths close to the pathological threshold, as a sequence-
ased approach would reduce ambiguity and the risk of false-
ositive/negative test results. Combined with previous data on the
ntergenerational instability of HTT alleles lacking CAA repeat in-
erruptions, these data suggest that sequence-level genotypes will
lso enable provision of more accurate risk assessments to off-
pring for prospective parents. These data reveal CAG length as a
ore accurate predictor of disease outcomes rather than encoded-
lutamine repeat length. This has implications for understanding
he pathogenic events in HD, and the interpretation of apparently
isease-moderating repeat interruptions in related disorders also
aused by the expansion of polyglutamine-encoding CAG repeats
hich may also act through effects on somatic expansion rather
han the assumed effects on protein structure. They also support a
ovel approach to therapy via gene editing, by introduction of syn-
nymous DNA-stabilising interruptions. Our data establish somatic
xpansion in blood DNA as a molecular phenotype, and, combined
ith previous data on somatic expansion of the HTT CAG repeat
n brain and animal models, suggest that some genetic modiﬁers
f HD clinical outcomes may operate via effects on somatic ex-
ansion of the CAG repeat. Combined, these data support somatic
xpansion of the CAG repeat as a novel therapeutic target in HD,
nd likely in other repeat expansion disorders, reveal a potential
eripheral biomarker of somatic expansion for clinical trials, and
ighlight FAN1, MLH1, MSH3 and MLH3 as potential drug targets.
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H1. Introduction
Huntington disease (HD) is one of a number of disorders in-
cluding many of the spinocerebellar ataxias, dentatorubral palli-
doluysian atrophy, and spinal and bulbar muscular atrophy, caused
by the expansion of a genetically unstable CAG/CAA repeat encod-
ing a toxic polyglutamine protein and characterised by extreme
variability in age at onset (AAO) [1]. HD is caused by the expan-
sion of a CAG repeat in exon one of HTT and the most common
allele in Europeans is 17 CAG repeats. HD-associated alleles exceed
35 CAG repeats and penetrance increases to ∼100% by 40 repeats
[2,3]. HD alleles are unstable in the germline and frequently in-
crease in length from one generation to the next, with inheritance
of a single CAG increase reducing AAO by ∼2 years [2]. Disease-
associated alleles also display allele length-, age- and cell type-
dependent, and expansion-biased, somatic instability, with somatic
expansions exceeding 1000 CAG repeats in some striatal neurons
[4–8]. Although somatic expansion could provide an explanation
for the tissue-speciﬁcity and progressive nature of symptoms [4],
it has not been widely considered as a therapeutic target in HD
[9] and related disorders. However, recent data arising from an un-
biased genome-wide association study (GWAS) revealed signals in
DNA repair pathways as modiﬁers of age at onset [10], some of
which have previously been revealed as mediating somatic expan-
sions in mouse models [1].
In a typical HTT allele, the pure CAG repeat (CAG copy num-
ber=Q1) is followed immediately downstream by an additional
glutamine-encoding CAACAG cassette (number of additional glu-
tamines encoded by this region=Q2, Fig. 2, Table 1). Thus, the
total number of consecutive glutamines encoded by this region
(QT) is typically equal to the number of pure CAGs, plus two
(QT =Q1 + Q2). The standard approach to genotyping in HD is to
use PCR and fragment length analysis to infer the number of pure
CAGs (QFL) assuming the typical allele structure (i.e. Q1 =QFL, as-
suming Q2 =2) [11]. Sequence variants in which the CAACAG cas-
sette is either deleted (Q2 =0), or duplicated (Q2 =4), have been
reported (Table S1, appendix). In these cases, CAG length estimated
by fragment length analysis may not equal the number of pure
CAGs (i.e. QFL = Q1). The glutamine-encoding CAG/CAA tract is
followed downstream by a proline-encoding CCA/CCG/CCT repeat
tract, that although polymorphic (Fig. 2, Table 1), has no apparent
impact on HD AAO [12].
In other repeat expansion disorders, variant repeat interrup-
tions modify mutational dynamics and disease severity [1]. We hy-
pothesised that CAG repeat sequence variants in HTT exon one,
and DNA repair gene variants, may directly modify somatic expan-
sion and consequent HD outcomes. Here, we sought to test these
hypotheses by high-throughput ultra-deep DNA sequencing to re-
veal allele structure and quantify somatic expansions in individuals
carrying disease-associated HTT alleles and to correlate these data
with HD clinical outcomes and DNA repair gene variants.
2. Methods
2.1. Study design and populations
The aim of the study was to sequence the HTT CAG/CAA re-
peat, quantify somatic expansions, genotype candidate DNA repair
gene polymorphisms and correlate these data with HD clinical out-
comes. As a discovery cohort, we selected 203 participants carry-
ing disease-associated HTT alleles with from 40 to 50 CAG repeats
with progression scores from TRACK-HD (105 premanifest, and 98
manifest for motor symptoms) (Table 2) (Supplementary methods
in appendix). As a replication cohort, we selected 543 participants
carrying disease-associated HTT alleles with from 40 to 50 CAG re-
peats from Enroll-HD, of which 531 had all of the data available forenotype to phenotype analyses (141 premanifest, and 390 man-
fest for motor symptoms) (Table 2) (Supplementary methods in
ppendix) [13].
.2. Procedures
Participants were recruited to TRACK-HD between 2008 and
011 [14], and Enroll-HD from 2012 [13]. Clinical and genetic data
ere obtained from CHDI, and new genetic data generated, for
RACK-HD participants between October 2015 and October 2016,
nd Enroll-HD between June 2016 and December 2017. The pri-
ary HD clinical outcomes we considered in our analyses were:
otor AAO; Uniﬁed Huntington’s Disease Rating Scale (UHDRS) to-
al motor score (TMS) [15]; UHDRS total functional capacity (TFC)
15]; and TRACK-HD progression score (Supplementary methods in
ppendix) [14].
.3. HTT exon one repeat region sequencing and genotyping
The HTT exon one repeat region was ampliﬁed from 20 ng of
lood DNA using MiSeq-compatible PCR primers, sequenced on
iSeq [16] and genotyped using ScaleHD (v0.251) (Supplemen-
ary methods in appendix). The ratio of somatic CAG expansions
number of somatic expansion products
number of progenitor allele products
)
was quantiﬁed from the MiSeq
ead count distributions (see details in Supplementary methods in
ppendix).
.4. Selection of candidate SNPs and genotyping
Full details of candidate SNP selection and genotyping are pro-
ided in section I.1.9 of the appendix.
.5. Statistical analyses
Statistical analyses were undertaken in R (v3.4.3) [17] using
Studio (version 1.0.153, see appendix for a full a list of R func-
ions and packages used) [18]. All individuals are represented once
n each analysis. Each data point represents a single baseline value
or each participant except for three-year longitudinal data avail-
ble in TRACK-HD for TMS and TFC. These longitudinal TMS and
FC data were used to express the inﬂuence of Q2 and the so-
atic expansion score on the progression score in units of clin-
cal measurements that are more commonly used (i.e. TMS and
FC). To do so, participant-speciﬁc slopes derived from mixed ef-
ect models with correlated random intercepts and slopes (with
ﬁxed ‘years of follow-up’ effect and a random ‘participant’ ef-
ect) were used as participant-speciﬁc rate of change in TMS and
FC (TMSrate and TFCrate). Multiple linear regressions were per-
ormed to investigate the association of ‘CAG’ length (QT or Q1),
umber of additional glutamine codons (Q2), and age, with the ra-
io of somatic CAG expansions (models SEQT, SEQ1 and SEQ1Q2),
nd derive an age- and pure CAG (Q1)-corrected individual-speciﬁc
omatic expansion score. Multivariate time-to-event analyses were
arried out using stratiﬁed Cox proportional hazard regressions to
nvestigate the association of ‘CAG’ length (QT, Q1 or QFL), num-
er of additional glutamine codons (Q2) and the somatic expan-
ion score with the time-to-onset of HD motor symptoms (mod-
ls AAOQT, AAOQ1, AAOQ1Q2 and AAOQFLQ2). For individuals with-
ut HD motor onset, the censored time was the age at the last
RACK-HD or Enroll-HD periodic dataset 3 visit. Cohort and sex
ere considered as strata in all Cox regressions. We conﬁrmed that
he proportional hazard assumption could be assumed for each
ox regression model ﬁt and each covariate (p>0·106). To derive
elative effect sizes, adjusted survival curves and median time to
D motor onset for the different numbers of additional glutamine
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Table 1
Allele structures observed at the HTT exon one repeat locus.
Allele structure code
Q1-Q2-P1-P2-P3
DNA sequence Variant annotation
(CAG)Q1(CAACAG)Q2/2(CCGCCA)P1/2(CCG)P2(CCT)P3
Glutamines
Total (Q1 +Q2)
Prolines
Total (P1 +P2 + P3)
Allele frequency (%) [n individuals]
TRACK-HD [203] Enroll-HD [543]
Non-disease Disease Non-disease Disease
Q1-2-2-P2-2 (CAG)Q1(CAACAG)1(CCGCCA)1(CCG)P2(CCT)2 Q
1 + 2 P2 + 4 94·09 [191] 96·06 [195] 91·53 [497] 97·61 [530]
LRG_763:c.52_153CAG[Q1]CAACAG[1]CCGCCA[1]CCG[P2]CCT[2]
Q1-4-2-7-3 (CAG)Q1(CAACAG)2(CCGCCA)1(CCG)7(CCT)3 Q
1 + 4 P2 + 5 3·86 [8] 2·96 [6] 2·95 [16] 1·29 [7]
LRG_763:c.52_153CAG[Q1]CAACAG[2]CCGCCA[1]CCG[7]CCT[3]
17-2-0-6-2 (CAG)17(CAACAG)1(CCGCCA)0(CCG)6(CCT)2 Q
1 + 2 P2 + 2 - - 0·18 [1] -
LRG_763:c.52_153CAG[17]CAACAG[1]CCGCCA[0]CCG[6]CCT[2]
Q1-2-0-9-2 (CAG)Q1(CAACAG)1(CCGCCA)0(CCG)9(CCT)2 Q
1 + 2 P2 + 2 1·48 [3] - 4·97 [27] -
LRG_763:c.52_153CAG[Q1]CAACAG[1]CCGCCA[0]CCG[9]CCT[2]
Q1-2-2-9-3 (CAG)Q1(CAACAG)1(CCGCCA)1(CCG)9(CCT)3 Q
1 + 2 P2 + 5 0·49 [1] - 0·18 [1] -
LRG_763:c.52_153CAG[Q1]CAACAG[1]CCGCCA[1]CCG[9]CCT[3]
Q1-0-2-7-2 (CAG)Q1(CAACAG)0(CCGCCA)1(CCG)7(CCT)2 Q
1 P2 + 4 - 0·49 [1] - 0·55 [3]
LRG_763:c.52_153CAG[Q1]CAACAG[0]CCGCCA[1]CCG[7]CCT[2]
20-0-2-11-2 (CAG)20(CAACAG)0(CCGCCA)1(CCG)11(CCT)2 Q
1 P2 + 4 - - 0·18 [1] -
LRG_763:c.52_153CAG[20]CAACAG[0]CCGCCA[1]CCG[11]CCT[2]
41-0-0-9-2 (CAG)41(CAACAG)0(CCGCCA)0(CCG)9(CCT)2 Q
1 P2 + 2 - 0·49 [1] - -
LRG_763:c.52_153CAG[41]CAACAG[0]CCGCCA[0]CCG[9]CCT[2]
Q1-0-0-11-2 (CAG)Q1(CAACAG)0(CCGCCA)0(CCG)11(CCT)2 Q
1 P2 + 2 - - - 0·37 [2]
LRG_763:c.52_153CAG[Q1]CAACAG[0]CCGCCA[0]CCG[11]CCT[2]
41-3-2-7-2 (CAG)41(CAA)1(CAACAG)1(CCGCCA)1(CCG)7(CCT)2 Q
1 + 3 P2 + 4 - - - 0·18 [1]
LRG_763:c.52_153CAG[41]CAA[1]CAACAG[1]CCGCCA[1]CCG[7]CCT[2]
See Fig. 2 for further details of allele structures. Q1 =number of pure CAGs; Q2 = the number of downstream glutamine-encoding CAA/CAG repeats; P1 =number of CCG/CCA proline codons upstream of the pure CCG repeat
tract; P2 =number of pure CCGs; P3 =number of CCT repeats. Disease-associated alleles with either zero, three or four downstream glutamine codons (Q2 =0, 3 or 4), are indicated with a red upward triangle, green diamond,
or green downward triangle, respectively. The variant annotation describes the HTT exon one sequence variants using the Sequence Variant Nomenclature of the Human Genome Variation Society based on the HTT Locus
Reference Genomic sequence LRG_763.
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Table 2
Participant characteristics. Participants excluded from the data analyses are not included.
Characteristics TRACK-HD Enroll-HD TRACK-HD and Enroll-HD
Number of individuals 203 531 734
Range of age at DNA sampling (years) 18·63 to 64·13 18·42 to 75·50 18·42 to 75·50
Mean age at DNA sampling (years (SD)) 45·00 (9·93) 48·84 (12·25) 47·78 (11·77)
Range of age at baseline (years) 18·63 to 64·13 18·42 to 75·50 18·42 to 75·50
Mean age at baseline (years (SD)) 44·96 (9·90) 48·84 (12·25) 47·77 (11·77)
Sex= female (%) 54·68 53·67 53·95
Manifest for Huntington disease motor symptoms 48·28% 73·45% 66·49%
Mean age at onset of motor symptoms (years (SD)) 45·27 (8·89) 45·85 (10·72) 45·73 (10·37)
Mean total motor score at baseline (SD) 12·06 (12·64) 23·58 (20·40) 20·40 (19·27)
Mean total functional capacity at baseline (SD) 11·93 (1·73) NA NA
Mean pure CAG (Q1) in the disease-associated allele (SD) 43·14 (2·16) 43·25 (2·40) 43·22 (2·33)
Mean total encoded glutamine (QT) in the disease-associated allele (SD) 45·18 (2·25) 45·26 (2·42) 45·24 (2·37)
Mean fragment length estimate of CAG (QFL) in the disease-associated allele (SD) 43·15 (2·21) 43·25 (2·42) 43·22 (2·36)
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ecodon categories (Q2), and positive and negative somatic expan-
sion scores, were estimated based on the mean values of the other
covariates. Multiple linear regressions were performed to investi-
gate the association of ‘CAG’ length (QT, Q1 or QFL), number of
additional glutamine codons (Q2), age and the somatic expansion
score with the progression score (models ProgQ1 and ProgQFL),
TMSrate (model TMSrateQ1Q2), TFCrate (model TFCrateQ1Q2) and
baseline TMS (models TMSQT, TMSQ1, TMSQ1Q2 and TMSQFLQ2).
In the Cox and linear regression analyses, all continuous explana-
tory variables (QT, Q1, QFL, age, baseline TMS, and baseline TFC)
were centred, except for the somatic expansion score, which, as a
regression residual was effectively already quasi-centred. We com-
pared the goodness of ﬁt of regression models containing the same
degrees of freedom (i.e. regression with QT vs regression including
Q1) via nonparametric bootstrapping of the r2 (for multiple linear
regressions) or the log-likelihood (for Cox proportional hazard re-
gressions) statistic. We performed 5000 bootstrap replications and
estimated the conﬁdence interval via the bias-corrected acceler-
ated (BCA) method [19,20]. ANOVA was used to compare regres-
sion models containing, or not containing, the number of addi-
tional encoded-glutamines (Q2) as a covariate (model SEQ1 com-
pared to SEQ1Q2, model AAOQ1 compared to AAOQ1Q2, and model
TMSQ1 compared to TMSQ1Q2). For each comparison, the p-value
associated with the ANOVA test-statistic (F for linear regressions
and χ2 for Cox regressions) was then estimated based on 105 per-
mutations of the number of additional encoded-glutamines (Q2).
In order to avoid potential biases in p-value estimates due to small
sample sizes for some levels of the number of additional glutamine
codons (Q2), for all linear and Cox regressions containing the num-
ber of additional glutamine codons (Q2) as a covariate (i.e. SEQ1Q2,
AAOQ1Q2, AAOQFLQ2, ProgQ1, ProgQFL, TMSrateQ1Q2, TFCrateQ1Q2,
TMSQ1Q2, TMSQFLQ2), all the Q2-associated p-values were esti-
mated based on the t- (for the linear regressions) or z-statistic (for
the Cox regressions) using 105 permutations of the number of ad-
ditional glutamine codons (Q2). The effect size for each number
of additional glutamine codons (Q2) genotype on the progression
score, TMSrate, TFCrate, and baseline TMS, was derived from the
least-square means (i.e. the means for each number of additional
glutamine codons (Q2) genotype adjusted for all other variables
in the linear regression). All statistical analyses were two-sided
and included sex, cohort and age at baseline (when appropriate)
as covariates. Participants with missing data were excluded from
relevant analyses (Fig. 1). PLINK (v1.07) [21] and gPLINK (version
2.050; http://zzz.bwh.harvard.edu/plink/gplink.shtml) were used to
test for Hardy-Weinberg equilibrium and the association between
SNPs and somatic expansion score by linear regression with sex as
a covariate. Meta-analyses of the association between SNPs and so-
matic expansion score were performed using sample size-weighted pnalysis (based on p-values) in METAL [22]. Within each set of
nalyses (AAO, progression score, rate of change of TMS and TFC,
aseline TMS, SNP association), the Benjamini-Hochberg false dis-
overy rate (FDR) procedure was used to correct for multiple test-
ng [23].
. Results
We analysed data from 203 participants from a TRACK-HD dis-
overy cohort and 543 from an Enroll-HD replication cohort (Fig.
, Table 2). DNA sequencing revealed that>95% of HTT alleles
omprised the typical glutamine-encoding repeat structure where
here was a single copy of the CAACAG cassette (Q2 =2) (Fig. 2,
able 1). We also detected three atypical glutamine-encoding re-
eat structures with either duplication (Q2 =4, n=13), or deletion
Q2 =0, n=7), of the glutamine-encoding CAACAG cassette, or an
dditional CAA between the pure CAG tract and the CAACAG cas-
ette (Q2 =3, n=1) on the disease-associated chromosome (Fig. 2,
able 1). As expected, alleles with deletion of the CAACAG cas-
ette (Q2 =0, n=7) yielded fragment length CAG estimates (QFL)
wo repeats shorter than the pure CAG number (Q1). Surprisingly,
ll the disease-associated alleles with duplication of the CAACAG
assette (Q2 =4, n=13) yielded fragment length estimates (QFL)
nly one repeat longer than the pure CAG (Q1), rather than the
xpected two (Figure S1A, appendix). These discrepancies presum-
bly reﬂect mispriming of the PCR primer used for fragment length
nalysis that binds across the polymorphic region between the
AG and CCG tracts, yielding artefactual fragment length estimates
QFL) that have no direct biological correlate (i.e. when Q2 =4,
1 = QFL = QT − 2) (Figure S1B–F, appendix).
Although somatic expansions in HD patient brain tissue may be
ery large [4], the level of somatic mosaicism in peripheral tissues
s low, but allele length-dependent and expansion-biased [7,8,24].
ere, sequencing of single input molecules of DNA revealed high
evels of smaller PCR slippage products, but only a low proportion
f products larger than the progenitor molecule (Figures S2 and
3, appendix). These data suggest the vast majority of expansion
roducts detected in bulk DNA analyses of disease-associated alle-
es represent genuine somatic expansions (Figure S3C, appendix).
he ratio of somatic expansions
(
number of somatic expansion products
number of progenitor allele products
)
epresents a quantitative measure of the degree of somatic expan-
ion present in the blood DNA of an individual at a given point.
iven the stabilising effects of repeat interruptions in other disor-
ers [1], it was not surprising that the ratio of somatic expansions
as best predicted by an interaction between age at sampling and
he length of the pure CAG repeat (Q1), rather than the total
ncoded-glutamine length (QT) (model SEQT r2QT =0·822,
< 2×10−16, model SEQ1 r2Q1 =0·836, p < 2×10−16, Table
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Fig. 1. Study design and sample exclusions.
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Fig. 2. Allelic variation at the HTT exon one repeat locus. The schematic diagram shows the typical reference allele structure of the CAG/CCG repeat region in exon one
of HTT (top). We here deﬁne the number of pure CAGs as Q1 and the number of additional downstream glutamine-encoding CAA/CAG repeats as Q2. Thus, total encoded-
glutamine QT =Q1 + Q2. We here deﬁne the number of copies of the proline codons before the pure CCG repeat as P1, the number of pure CCGs as P2, and the number of
copies of the CCT proline codons as P3. Thus, total encoded-proline PT =P1 + P2 + P3. The ﬁgure shows schematic representations of the atypical alleles observed. Repeat
codons are depicted: CAG glutamine codons as red boxes; CAA glutamine codons as green boxes; CCG proline codons as blue boxes; CCA proline codons as yellow boxes;
and CCT proline codons as pink boxes. Disease-associated alleles with either zero, three or four downstream glutamine codons (Q2 =0, 3 or 4), are indicated with a red
upward triangle, green diamond, or green downward triangle, respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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sS2, appendix, Fig. 3A) (difference in r2 =0·014 (95% CI=0·005
to 0·025)). Once corrected for pure CAG (Q1), the number of
additional CAA/CAG codons (Q2) had no impact on the ratio of
somatic expansions in blood DNA (model SEQ1Q2 pFDRQ2=0 =0·36,
pFDRQ2=4 =0·36, pFDRQ2=0∗Age =0·12, pFDRQ2=4∗Age =0·51, Table
S2, appendix) (permutation test for difference between models
SEQ1Q2 and model SEQ1, p=0·10). The ratio of somatic expansions
corrected for age at sampling, the number of pure CAG repeats
(Q1), sex and cohort (model SEQ1) represents an individual-speciﬁc
somatic expansion score.
Motor AAO in HD is strongly predicted by the number of
‘CAG’ repeats inherited as estimated by PCR fragment length anal-
ysis (QFL) [25]. However, the existence of atypical CAG/CAA struc-
tures allows us to ask whether HD clinical outcomes are best
predicted by the length of the longest pure CAG tract (Q1), or
by the total number of consecutive glutamines encoded by the
CAG/CAA repeat (QT). In addition, the availability of individual-
speciﬁc somatic expansion scores, allows us to assess whether
somatic expansions in blood are associated with variation in
AAO. We thus performed multivariate time-to-event Cox propor-
tional hazard regression analyses of variation in AAO (time to
HD onset) dependent on ‘CAG’ length (pure CAG (Q1) or total
encoded-glutamine length (QT)), and the somatic expansion score.
Pure CAG length (Q1) was a better predictor of AAO than to-
tal encoded-glutamine (QT)(model AAOQT log-likelihood=−1899,
model AAOQ1 log-likelihood=−1884, 95% CI of log-likelihood dif-
ference: 5·05 to 30·93, Table S3, appendix).
Although pure CAG length (Q1) was a better predictor of AAO
than total encoded glutamine length (QT), under the assumption
that the actual toxic element in cells is the polyglutamine pro-
tein [9], we might still expect that after correcting for the num-
ber of pure CAG repeats (Q1), fewer glutamine-encoding CAA/CAG
codons (Q2) would increase AAO (Figure S4, appendix). Surpris-
ingly, rather than increasing AAO relative to typical allele carri-
ers (Q2 =2), after correcting for pure CAG length (Q1), absence of
the CAACAG cassette (Q2 =0, n=7) was associated with an earlier
AAO of ∼10 years with a median age at HD onset=38 years (95%I=34 to 45) relative to 48 years (95% CI=46 to 49) for typical
lleles (Q2 =2) (pFDRQ2=0 =7·3×10−4, model AAOQ1Q2, Table S3,
ppendix) (Fig. 4A). After correcting for pure CAG length, dupli-
ation of the CAACAG cassette (Q2 =4, n=13) was not associated
ith an earlier AAO with a median time to HD onset=48 years
95% CI=45 to 54) (pFDRQ2=4 =0·95, model AAOQ1Q2, Table S3,
ppendix) (Fig. 4A).
The number of additional glutamine codons (Q2) was not as-
ociated with the length of the pure CAG tract (Q1) (r2 =0·001,
=0·17) (Figure S5, appendix). However, over the pure CAG (Q1)
ange of 40 to 50 repeats, there was a positive association between
he number of additional glutamine codons (Q2) and the length
f the total glutamine-encoding CAA/CAG repeat (QT) (r2 =0·034,
=2×10−7) (Figure S5, appendix). Some association was in-
vitable because the total glutamine length (QT) is sum of the
umber of pure CAGs (Q1) and the number of additional glu-
amine codons (Q2) (i.e. QT =Q1 + Q2). Furthermore, the pure
AG length selection criteria (40 ≤ Q1 ≤ 50) differentially elimi-
ates some genotypes at either end of the distribution: individu-
ls with QT =40 and Q2 =0 (and therefore Q1 =40) were included,
ut individuals with QT =40, and Q2 =2 (and therefore Q1 =38)
ere excluded; likewise, individuals with QT =53, and Q2 =4 (and
herefore Q1 =49) were included, but individuals with QT =53
nd Q2 =2 (and therefore Q1 =51) were excluded. This associa-
ion might also have been compounded by an ascertainment bias
hereby individuals with absence of the CAACAG cassette (Q2 =0)
ay have an increased probability of receiving a diagnosis with a
maller total encoded glutamine repeat length (QT).
In order to gauge the level of prognostic inaccuracy with the
tandard test, we revealed that relative to that predicted by frag-
ent length analyses (QFL) alone, absence of the CAACAG cassette
Q2 =0, n=7) was associated with an error in the predicted AAO of
16 years with a median age at HD onset=32 years (95% CI=29
o 39) relative to 48 years (95% CI=46 to 49) for typical alle-
es (Q2 =2) (pFDRQ2=0 < 1·5×10−5, model AAOQFLQ2, Table S3,
ppendix) (Fig. 4B). Conversely, duplication of the CAACAG cas-
ette (Q2 =4, n=13) appeared to be associated with an ∼3-year
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Fig. 3. Somatic expansion in Huntington disease. A) The ratio of somatic expansions of the HTT exon one CAG repeat is allele length and age-dependent. The graph shows
the ratio of somatic expansions
(
number of somatic expansion products
number of progenitor allele products
)
in blood DNA plotted against the age at sampling for 746 participants in the TRACK-HD and Enroll-HD cohorts.
Each point is colour coded with respect to the length of the inherited progenitor allele length (Q1). The scatterplot also shows the sex- and cohort-adjusted ﬁtted regression
lines for each pure CAG repeat length (Q1) derived from model SEQ1 which includes an interaction between age at sampling and pure CAG repeat length (Q1) (Table S2,
appendix). B) Somatic expansion scores in blood DNA predict age at onset in Huntington disease. The graph shows adjusted time to event curves from a Cox proportional
hazard model of HD motor onset according to the sign of the pure CAG somatic expansion score (determined using model SEQ1, Table S2, appendix). The solid lines represent
the age-dependent probability of HD motor onset: orange for participants with positive expansion scores; and green for participants with negative expansion scores. The light
shaded regions represent the 95% CI for the onset probability curves. A vertical tick mark on the curves indicates that a participant was censored at this time. Vertical dashed
lines indicate median survival for each somatic expansion score category: individuals with a positive blood DNA somatic expansion score had a median age at onset=46
years (95% CI 45 to 48); whilst individuals with a negative blood DNA somatic expansion score had a median age at onset=49 years (95% CI 47 to 50). (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Sater predicted AAO with a median time to HD onset=51 years
95% CI=48 to 59) (pFDRQ2=4 =0·11, model AAOQFLQ2, Table S3,
ppendix) (Fig. 4B).
If the accumulation of somatic expansions contributes to-
ard disease development, then individual-speciﬁc variation in
he rate of somatic expansion should be associated with vari-
tion in HD outcomes. As hypothesised, variation in AAO, cor-
ected for the number of pure CAG repeats (Q1), was correlated
ith the individual-speciﬁc somatic expansion scores in blood
NA (model AAOQ1Q2, hazard ratio=3·05, 95% CI=1·94 to 4·80,
FDRSE =2·8×10−6). Individuals with a positive blood DNA somatic
xpansion score (median age at onset=46, 95% CI 45 to 48) had
three year earlier median age at onset than individuals with a
egative blood DNA somatic expansion score (median age at on-
et=49, 95% CI 47 to 50) (Fig. 3B) i.e. individuals with more so-
atic expansions in blood DNA than average, had an earlier age at
nset than average.
Although AAO is of particular interest to patients, it can be diﬃ-
ult to assess, and it is unlikely to be a clinical trial outcome in the
ear term. However, careful clinical testing and imaging can reveal
ifferences in the premanifest HD population many years before
he onset of overt motor symptoms [2,26,27]. The TRACK-HD study
as established speciﬁcally to determine the utility of multiple
utcomes to assess disease progression in the late premanifest and
arly HD population as representative of likely trial cohorts. Pre-
iously, Hensman Moss et al., used principal component analysis
o combine 24 clinical variables, encompassing brain volume, cog-ition and motor performance, corrected for age and ‘CAG’ repeat
ength (QFL) to derive a progression score in TRACK-HD (appendix)
14]. This progression score also proved very sensitive for detect-
ng genetic modiﬁers of HD [14]. Here, the two individuals with
eletion of the CAACAG cassette (Q2 =0) in their disease-associated
llele ranked as the two fastest progressing TRACK-HD partici-
ants using the previously determined progression score based on
heir measured ‘CAG’ length (QFL) (Fig. 4C). Conversely, 5/6 carri-
rs of the CAACAG cassette duplication (Q2 =4) had a lower dis-
ase progression score than average (Fig. 4C). Regression analysis
onﬁrmed that relative to that predicted by the fragment length
stimate of CAG (QFL), absence of the CAACAG cassette (Q2 =0,
=2) was associated with a 3·1 unit (95% CI=1·8 to 4·4) increase
n the progression score (pFDRQ2=0 =1×10−4); and duplication of
he CAACAG cassette (Q2 =4, n=6) was associated with an appar-
nt −0·99 unit (95% CI=−1·76 to −0·22) decrease in the progres-
ion score (pFDRQ2=4 =0·028) (Fig. 4D, model ProgQFL, Table S4,
ppendix). When the disease progression score was re-calculated
sing the length of the pure CAG repeat (Q1), the protective ef-
ect of the number of additional glutamine codons (Q2) was re-
uced, but remained apparent: absence of the CAACAG cassette
Q2 =0, n=2) was associated with a 2·2 unit (95% CI=0·9 to 3·6,
FDRQ2=0 =0·014) increase in the progression score; and duplica-
ion of the CAACAG cassette (Q2 =4, n=6) was nominally associ-
ted with a −0·74 unit (95% CI=−1·54 to 0·05, pFDRQ2=4 =0·110)
ecrease in the progression score (Fig. 4E/F, model ProgQ1, Table
4, appendix). Individuals with higher somatic expansion scores
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Fig. 4. Associations between HTT exon one CAG repeat structures and HD clinical outcomes and biases associated with the prediction of HD clinical outcomes based on
fragment length estimates of CAG. The adjusted probability curves of age at HD motor onset (A/B) show the probability of motor onset predicted on the basis of the pure
CAG length (Q1, A) or the fragment length estimate of CAG (QFL, B) for each number of additional glutamine codons genotype (Q2 =0, red; Q2 =2, black; Q2 =4, green). The
light shaded regions represent the 95% CI for the onset probability curves. A vertical tick mark on the curves indicate that a participant was censored at this time. Vertical
dashed lines indicate median survival for each Q2 genotype. For the pure CAG (Q1) estimates (A): individuals Q2 =0 had a median age at onset=38 years (95% CI=34 to
45); individuals Q2 =2 had a median age at onset=48 years (95% CI=46 to 49); and individuals Q2 =4 had a median age at onset=48 years (95% CI=45 to 54). For the
CAG fragment length (QFL) estimates (B): individuals Q2 =0 had a median age at onset=32 years (95% CI=29 to 39); individuals Q2 =2 had a median age at onset=48
years (95% CI=46 to 49); and individuals Q2 =4 had a median age at onset=51 years (95% CI=48 to 59). The scatterplots (C/E) and the whisker plots (D/F) show the
ranked TRACK-HD progression score predicted on the basis of the fragment length estimate of CAG (QFL, C/D) or pure CAG (Q1, E/F) dependent on the number of additional
glutamine codons (Q2). The progression scores are normally distributed around zero, with zero representing the population average disease progression. Negative values
represent individuals with slower than average disease progression and positive values represent individuals with faster than average disease progression. The whisker plots
show the mean (diamond) and 95% CI (whiskers) on the basis of the fragment length estimate of CAG (QFL, E) or pure CAG length (Q1, F) dependent on the number of
additional glutamine codons (Q2 =0, red; Q2 =2, black; Q2 =4, green). The whisker plots (G/H/I/J) show the least-square means for the rate of change of TMS (TMS rate, G)
and TFC (TFC rate, H) predicted on the basis of the pure CAG length (Q1), and TMS predicted on the basis of the pure CAG (Q1, G) or fragment length estimate of CAG (QFL,
H) for each number of additional glutamine codons (Q2) genotype (i.e. the means associated with each number of additional glutamine codons (Q2) genotype adjusted for
all other variables in the linear regression).
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0were also revealed as having higher TRACK-HD progression scores:
a one-unit increase in the blood DNA somatic expansion score was
associated with a 0·98 unit increase in the pure CAG (Q1) progres-
sion score (95% CI=0·24 to 1·72, pFDRSEQ1 =0·028, model ProgQ1,
Table S4, appendix).
Sensitive as the TRACK-HD progression score is as a detector
of genetic modiﬁers, it is hard to relate to individual features of
the disease. Thus, in order to increase the interpretability of the
overall effects on progression, we determined the effect sizes of
the sequence of the CAG/CAA repeat and the somatic expansion
score on the rate of change of total motor score (TMS) and the
total functional capacity (TFC) score. TMS and TFC score are com-
ponents of the TRACK-HD progression score that are widely used,
sensitive clinical outcome measures of HD (note that a higher TMS,nd a lower TFC, is a worse outcome) [15]. These analyses revealed
hat after correcting for baseline TMS, age and the length of the
ure CAG tract (Q1), absence of the CAACAG cassette (Q2 =0, n=2)
as nominally associated with a faster rate of increase of TMS
f ∼1 units year−1 (95% CI=−0·9 to 2·8, pFDRQ2=0 =0.328) and a
aster rate of decrease of TFC of ∼-0·8 units year−1 (95% CI=−1·5
o −0·2, pFDRQ2=0 =0.038), whilst presence of the CAACAG du-
lication (Q2 =4, n=6) appeared to be associated with a slower
ate of increase in TMS of ∼-0·3 units year−1 (95% CI=−1·4 to
·9, pFDRQ2=4 =0·66) and a slower rate of decrease in TFC of
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Table 3
Genetic modiﬁers of blood DNA somatic expansion scores of the HTT CAG repeat. Shown is the genetic association data for the six SNPs genotyped in TRACK-HD and
replicated in Enroll-HD. Additional details of all the SNPs analysed are provided in Table S7 (appendix). SNPs are ordered by decreasing p-value of their association with
the somatic expansion score in the TRACK-HD cohort. Chr: chromosome. A1: minor allele. β: regression coeﬃcient. p: unadjusted p-value. p FDR: p-value adjusted for
multiple testing using the Benjamini-Hochberg false discovery rate correction. ∗Note that in a preliminary analysis using a slightly larger TRACK-HD cohort including four
participants with 39 pure CAG repeats (Q1 =39) and six non-Caucasians, the association between somatic expansion score and rs20579 in LIG1 was p=0·072, and rs20579
was thus selected for replication in Enroll-HD.
SNP ID Chr Gene A1 A2 TRACK-HD Enroll-HD Meta-analysis
β p p FDR β p p FDR p FDR
rs3512 15 FAN1 C G 0·060 0·003 0·034 0·050 6·7× 10−5 4·0×10−4 4·8× 10−6
rs175080 14 MLH3 A G −0·053 0·004 0·034 −0·029 0·013 0·026 8·0× 10−4
rs147804330 2 RP11-481J13.1 A G −0·107 0·010 0·073 0·003 0·912 0·912 0·246
rs1382539 5 MSH3 A G −0·045 0·018 0·101 −0·023 0·077 0·116 0·009
rs1799977 3 MLH1 G A −0·032 0·093 0·314 −0·034 0·009 0·026 0·004
rs20579 19 LIG1 A G −0·042 0·112∗ 0·314 −0·002 0·908 0·912 0·351
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S0·1 units year−1 (95% CI=−0·2 to 0·5, pFDRQ2=4 =0·53) (Ta-
le S5, models TMSrateQ1Q2 and TFCrateQ1Q2, appendix) (Fig.
G/H). A one-unit increase in the blood DNA somatic expan-
ion score was nominally associated with a 1·7 unit year−1 (95%
I=0·7 to 2·8, pFDRSEQ1 =0·002) acceleration in the rate of in-
rease of TMS and with a −0·12 unit year−1 (95% CI=−0·46 to
·23, pFDRSEQ1 =0·561) acceleration in the rate of decrease of TFC
Table S5, models TMSrateQ1Q2 and TFCrateQ1Q2, appendix).
TMS was also available for Enroll-HD, thus in order to assess
he generalisability of the TRACK-HD data, we also determined if
aseline TMS was associated with the sequence of the CAG/CAA
epeat and the somatic expansion score. In the combined co-
orts, pure CAG length (Q1) was a better predictor of age-adjusted
aseline TMS than total encoded-glutamine (QT) (model TMSQT
2 =0·558, model TMSQ1 r2 =0·578, Table S6, appendix) (differ-
nce in r2 =0·020 (95% CI=0·0098 to 0·036)). Higher TMS is a
orse outcome and these analyses revealed that after correcting
he age-adjusted TMS for pure CAG (Q1), absence of the CAACAG
assette (Q2 =0, n=7) was associated with an increase in base-
ine TMS of ∼2·3 units with a mean baseline TMS=6·2 units (95%
I=5·1 to 7·4) relative to 3·9 units (95% CI=3·8 to 4·1) for typ-
cal alleles (Q2 =2) (pFDRQ2=0 =1·9×10−4, model TMSQ1Q2, Table
6, appendix) (Fig. 4I). Duplication of the CAACAG cassette (Q2 =4,
=13) was not associated with a lower TMS=3·9 units (95%
I=3·1 to 4·7) (pFDRQ2=4 =0·92, model TMSQ1Q2, Table S6, ap-
endix) (Fig. 4I). If instead, the age-adjusted TMS was corrected for
he fragment length estimate of CAG (QFL), absence of the CAACAG
assette (Q2 =0, n=7) was associated with an increase in base-
ine TMS of ∼3·7 units with a mean baseline TMS=7·6 units (95%
I=6·5 to 8·8) relative to 3·9 units (95% CI=3·8 to 4·1) for typi-
al alleles (Q2 =2) (pFDRQ2=0 =1·9×10−5, model TMSQFLQ2, Table
6, appendix) (Fig. 4J). Duplication of the CAACAG cassette (Q2 =4,
=13) appeared to be associated with a 0·8 unit lower TMS with a
ean TMS=3·1 years (95% CI=2·3 to 4·0) (pFDRQ2=4 =0·08, model
MSQFLQ2, Table S6, appendix) (Fig. 4J). Individuals with higher so-
atic expansion scores were also revealed as having higher TMS
pFDRSEQ1 =2·5×10−4, model TMSQ1Q2, Table S6, appendix).
To determine whether DNA repair gene variants found to
odify HD outcomes [10,14] might act by modifying somatic
xpansion, we genotyped 28 candidate SNPs in the discov-
ry TRACK-HD cohort (Table 3, Table S7, appendix). Although
ve SNPs were nominally signiﬁcantly (p < 0·05) associated
ith the somatic expansion scores, only three SNPs at the
LH3 and MTMR10/FAN1 loci remained signiﬁcant after cor-
ection for multiple testing (pFDRrs175080 =0·034 in MLH3, and
FDRrs2140734 and pFDRrs3512 =0·034 at the MTMR10/FAN1 lo-
us, Table 3, Table S7, appendix). To replicate these effects in
nroll-HD, we selected six candidate SNPs that approached sta-
istical signiﬁcance in the TRACK-HD cohort (p < ∼0·1) and
hat could be genotyped using KASP assays. We revealed as-ociations with somatic expansion scores for variants in MLH3
pFDRrs175080 =0·026), FAN1 (pFDRrs3512 =4·0×10−4) and MLH1
pFDRrs1799977=0·026) in the Enroll-HD cohort (Table 3). Signals
or MLH3 (pFDRrs175080 =8·0×10−4), FAN1 (pFDRrs3512 =4·8×10−6)
nd MLH1 (pFDRrs1799977=0·004) were further ampliﬁed in a
eta-analysis of the TRACK-HD and Enroll-HD association tests,
hich also brought a variant in MSH3 below the nominal multi-
le testing signiﬁcance threshold (pFDRrs1382539=0·009, Table 3,
able S7, appendix).
. Discussion
We used high-throughput ultra-deep sequencing to determine
he precise structure of the HTT exon one HD-causing repeat, and
imultaneously quantify somatic expansions, in two large cohorts
f carriers of HD-associated alleles. We established that, although
one of the DNA sequence variants detected changed the amino
cid sequence of the encoded polyglutamine repeat (beyond its
ength), the precise DNA sequence of the HTT polyglutamine-
ncoding repeat was associated with HD outcomes. Notably, HD
linical outcomes were best predicted by the number of pure
AG repeats (Q1) rather than the total number of consecutive
lutamine-encoding CAG/CAA repeats (QT) on the disease chro-
osome. The ﬁnding that duplication of the CAACAG cassette
Q2 =4) appeared to be associated with a later AAO compared
o that predicted using standard fragment length analysis (QFL)
s consistent with previous reports of a protective HTT haplotype
resent in a subset of Danish HD families [28]. Although not
riginally considered as a likely explanation, the protective HD
aplotype was revealed to carry the duplication of the CAACAG
assette (Q2 =4) [28] on a (CCGCCA)1(CCG)7(CCT)3 repeat haplo-
ype [29], identical to all 37 CAACAG cassette duplication alleles
e detected (Table 1) and in three previous reports (Table S1,
ppendix). The effects of absence or duplication of the CAACAG
assette with predicted age at onset have also been replicated in
wo very recent reports published while this paper was in review
30,31]. In the largest GWAS of modiﬁers of HD age at motor onset
et reported, the Genetic Modiﬁers of HD team identiﬁed a rare
rotective HTT haplotype, which, based on the fragment length
stimate of ‘CAG’ (QFL), delayed motor onset by ∼ 4 to 5 years and
as associated with the CAACAG cassette duplication (Q2 =4) and
CCGCCA)1(CCG)7(CCT)3 repeat haplotype [30]. Wright et al., also
ssociated the CAACAG cassette duplication (Q2 =4) with delayed
otor onset of ∼ 4 years based on the fragment length estimate of
CAG’ (QFL) [31]. The Genetic Modiﬁers of HD team also detected
n even rarer deleterious HTT haplotype, which, based on the
ragment length estimate of ‘CAG’, accelerated motor onset by ∼ 9
o 10 years, and was associated with loss of the CAACAG cassette
Q2 =0) and a (CCGCCA)0(CCG)12(CCT)2 repeat haplotype [30].
imilarly, Wright et al., associated the CAACAG cassette deletion
578 M. Ciosi, A. Maxwell and S.A. Cumming et al. / EBioMedicine 48 (2019) 568–580
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m(Q2 =0) with an accelerated age at onset of ∼29 years in carriers
of reduced penetrance alleles (36 to 39 ‘CAG’ repeats), and ∼ 13
years in carriers of full mutations (40 to 50 ‘CAG’ repeats), relative
to the age at onset predicted by the fragment length estimate
of ‘CAG’ (QFL) [31]. Interestingly, Wright et al., observed the loss
of the CAACAG cassette (Q2 =0) on either a (CCGCCA)0(CCG)10,
(CCGCCA)0(CCG)7 or (CCGCCA)1(CCG)10 repeat haplotype [31].
Notably, we have not observed the (CAACAG)0(CCGCCA)0(CCG)12,
(CAACAG)0(CCGCCA)0(CCG)10, (CAACAG)0(CCGCCA)0(CCG)7 or
(CAACAG)0(CCGCCA)1(CCG)10 disease-associated repeat haplotypes
in our data. Nonetheless, we observed a similar effect size com-
bining data from (CAACAG)0 (Q
2 =0) disease associated alleles
observed on three different (CCGCCA)P1(CCG)P2 repeat haplotypes
(Table 1). These data strongly suggest multiple origins for the
CAACAG cassette deletion alleles (Q2 =0), and, that the size of
the modifying effect of loss of the CAACAG cassette (Q2 =0) is
overestimated due to the mis-sizing the pure CAG repeat tract
(Q1) by fragment length analysis and is not mediated by some
other linked modiﬁer. The ﬁnding that fragment length analysis
of HTT CAG length is inaccurate in subjects with atypical alle-
les has implications for clinical trials with CAG repeat length
inclusion criteria, potentially modifying the predicted AAO by
from approximately −16 to +3 years. These ﬁndings also have
implications at the lower end of the disease-associated CAG
range where discrepancies of +/- one to two CAG repeats could
move an allele between the non-pathogenic and low pene-
trance ranges, or between the low and fully penetrant ranges.
As atypical disease-associated HTT alleles are relatively rare,
additional larger and more detailed studies will be needed to
better predict absolute effect sizes on HD outcomes for each
speciﬁc structure. Nonetheless, these ﬁndings have implications
for genetic diagnosis and counselling, and support a move toward
sequence-based diagnosis and genetic stratiﬁcation in HD clinical
trials.
A possible explanation for the greater predictive power of pure
CAG (Q1) as opposed to total encoded-glutamine length (QT), is
that somatic expansion of the CAG repeat is a driver of disease
pathology. This interpretation is supported by the observation that
somatic expansion scores in blood DNA were, as expected [1], best
predicted by the length of the pure CAG repeat (Q1). Moreover,
we were also able to determine that individuals with higher so-
matic expansion scores in blood DNA, had worse clinical outcomes
than average. In further support of a direct role for somatic expan-
sions in mediating pathology in HD, we showed that some DNA
repair gene variants revealed by GWAS to associate with HD out-
comes [10,14,30], also associate with somatic expansion scores in
blood DNA, consistent with the role of these genes in generating
expansions in model systems [1,32]. However, the effect for MSH3
was modest and we were not able to detect associations with LIG1,
PMS1, and PMS2, possibly as a limitation of the sample size. A role
for somatic expansion in driving brain pathology is supported by
the ﬁnding that a greater frequency of large expansions in the cor-
tex of end-stage patients is associated with extreme early AAO in
HD relative to that predicted using fragment length analysis (QFL)
[33]. Thus, unless somatic expansions in blood DNA are directly
impacting on primarily neurological disease outcomes, then the
associations between somatic expansion scores in blood and dis-
ease outcomes, suggest that the dynamics of HTT somatic expan-
sion measured in blood broadly parallel those in the brain (Figure
S6, appendix). Additional data are required to evaluate directly the
degree of comparability between somatic expansion dynamics in
blood and brain. A role for pure CAG length in driving pathology
via somatic expansion may also apply to other disorders associ-
ated with the expansion of polyglutamine-encoding repeats, such
as SCA1, in which repeat interruptions also appear to modify dis-
ease outcomes [34].It is also possible that the greater predictive power of the pure
AG (Q1) relative to the total number of consecutive encoded glu-
amines (QT) is not driven by somatic expansion, but other mech-
nisms. These could include: i) there is an additional effect of
inked variants, on, for instance, HTT transcription [29]; ii) there
re sequence-dependent effects on the HTT transcript, that might
odify folding [35], splicing [36], or canonical translation [37]; iii)
here are sequence-dependent effects on RAN translation, possi-
ly generating toxic polyalanine, polyserine, polyleucine or poly-
ysteine proteins from the sense or antisense transcript [38]; or, iv)
he toxic element is not the encoded protein, but toxic RNA [39].
Somatic expansion ratios were best predicted by the length of
he pure CAG repeat (Q1) and in our data there was no additional
tabilising effect of the number of copies of the CAACAG cassette.
ndeed, after correcting for pure CAG (Q1), there was a slight trend
or additional copies of the CAACAG cassette to be associated with
reater somatic expansion ratios. In contrast, Wright et al., have
ecently reported that the number of copies of the CAACAG cas-
ette does directly modify somatic mutational dynamics in blood
NA [31]. However, it should be noted that their somatic expan-
ion ratios have been corrected for the fragment length estimate
f ‘CAG’, and not the number of pure CAG repeats (Wright and
ayden, personal communication) [31]. In addition, most of their
ata derive from the analysis of reduced penetrance alleles (36 to
9 ‘CAG’ repeats). Larger studies will be required to further eval-
ate possible interactions between pure CAG length (Q1) and the
umber of copies of the CAACAG cassette on somatic expansions
n blood DNA.
Interestingly, correcting for pure CAG (Q1) does not appear to
ompletely eliminate the disease-moderating effect of the num-
er of additional glutamine codons (Q2). This effect appeared to be
ore pronounced for the deletion of the CAACAG cassette (Q2 =0),
han the duplication of the CAACAG cassette (Q2 =4). Nonetheless,
f the polyglutamine protein is the toxic entity in cells, correcting
or pure CAG would be expected to invert the disease-modifying
ffect of the number of copies of the CAACAG cassette, since alleles
ith more CAACAG cassettes will translate to proteins containing a
reater total number of toxic glutamines (Figure S4, appendix). In
ddition to a contribution of the alternative mechanisms outlined
bove, explanations for this could also include: i) the number of
dditional CAA/CAG codons has an additional stabilising effect on
omatic expansions in the brain, not reﬂected in somatic expan-
ion scores in blood; or ii) somatically acquired disease-relevant
xpansions in brain are so large, that +/− two glutamines are not
etectable/biologically relevant.
Our data, the GWAS results [10,14,30], and data on somatic ex-
ansions in HD brains [4–6,33], converge on somatic expansion
s a potential driver of disease pathology in HD. For the vari-
nts in MLH1 and MSH3, the directions of the effect in indepen-
ent association studies [10,14,30] are consistent, i.e. the alleles
e have associated with higher somatic expansion scores in blood
NA are associated with an earlier AAO [10] or more rapid dis-
ase progression [14]. However, for the variants in MLH3 and FAN1,
he effect directions are not consistent, i.e. alleles associated with
igher somatic expansion scores in blood DNA are associated with
ater AAO10 or slower disease progression [14]. Notably, both the
LH3 and FAN1 SNPs are revealed as bidirectional tissue-speciﬁc
xpression quantitative trait loci in the human Genotype-Tissue
xpression database [40] (Table S8, appendix) (i.e. the same al-
ele is associated with increased mRNA levels in some tissues and
ower in others). Thus, the causative variant could mediate oppo-
ite effects on FAN1/MLH3 expression and somatic expansion in
he haematopoietic stem cells from which circulating white blood
ells are derived, relative to the critical regions of the brain af-
ected in HD (Figure S6, appendix). Tissue-speciﬁc effects of genetic
odiﬁers might also explain the relatively modest associations
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Retween disease outcomes and blood DNA somatic expansions
cores, which, given the associations of DNA repair gene SNPs with
isease outcomes [10,14,30], might reasonably have been expected
o be more dramatic. Although confounded by the complexity of
he underlying biology, our data nonetheless reveal somatic ex-
ansion in blood as a potential peripheral biomarker of disease-
elevant modiﬁers of somatic expansion for genetic studies and
rug trials. To this end, longitudinal analyses of somatic expansion
ill be a key next step, in addition to the development of an assay
hat quantiﬁes somatic contractions.
By associating genetic modiﬁers of HD outcomes to individual-
peciﬁc somatic expansion scores, these data support somatic ex-
ansion as a factor in HD pathogenesis and further highlight FAN1,
SH3, MLH3 and MLH1 and other components of the expansion
athway and/or the sequence integrity of the CAG repeat tract as
otential therapeutic targets in this disorder. Although null alleles
n some DNA mismatch repair genes, such as MLH1 and MSH2 [41],
ave been associated with hereditary non-polyposis colon cancer,
he common DNA repair gene polymorphisms analysed here are
ot associated with an overt cancer predisposition phenotype, yet
re nonetheless associated with positive impacts on HD outcomes.
his suggests that pharmacological interventions that achieved a
imilar impact on DNA repair activity might be therapeutically
eneﬁcial and safe in HD and related repeat expansion disorders.
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